KEGG   DRUG: Evolocumab
Entry
D10557                      Drug                                   
Name
Evolocumab (USAN/INN);
Evolocumab (genetical recombination) (JAN);
Repatha (TN)
Product
Formula
C6242H9648N1668O1996S56
Exact mass
141700.9089
Mol weight
141789.0125
Sequence
(Heavy chain)
EVQLVQSGAE VKKPGASVKV SCKASGYTLT SYGISWVRQA PGQGLEWMGW VSFYNGNTNY
AQKLQGRGTM TTDPSTSTAY MELRSLRSDD TAVYYCARGY GMDVWGQGTT VTVSSASTKG
PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL
SSVVTVPSSN FGTQTYTCNV DHKPSNTKVD KTVERKCCVE CPPCPAPPVA GPSVFLFPPK
PKDTLMISRT PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTFRVVSVL
TVVHQDWLNG KEYKCKVSNK GLPAPIEKTI SKTKGQPREP QVYTLPPSRE EMTKNQVSLT
CLVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL YSKLTVDKSR WQQGNVFSCS
VMHEALHNHY TQKSLSLSPG K
(Light chain)
ESALTQPASV SGSPGQSITI SCTGTSSDVG GYNSVSWYQQ HPGKAPKLMI YEVSNRPSGV
SNRFSGSKSG NTASLTISGL QAEDEADYYC NSYTSTSMVF GGGTKLTVLG QPKAAPSVTL
FPPSSEELQA NKATLVCLIS DFYPGAVTVA WKADSSPVKA GVETTTPSKQ SNNKYAASSY
LSLTPEQWKS HRSYSCQVTH EGSTVEKTVA PTECS
(Disulfide bridge: H22-H96, H129-L124, H142-H198, H217-H'217, H218-H'218, H221-H'221, H224-H'224, H255-H315, H361-H419, H'22-H'96, H'129-L'214, H'142-H'198, H'255-H'315, H'361-H'419, L22-L90, L137-L196, L'22-L'90, L'137-L'196)
  Type
Peptide
Class
Hypolipidemic agent
 DG01946  Hypolipidemic agent
  DG03128  Anti-PCSK9 antibody and siRNA
Remark
Therapeutic category: 2189
ATC code: C10AX13
Product: D10557<JP/US>
Efficacy
Antihyperlipidemic, Anti-PCSK9 antibody
  Disease
Primary hyperlipidemia [DS:H01635]
Homozygous familial hypercholesterolemia [DS:H00155]
Heterozygous familial hypercholesterolemia [DS:H00155]
  Type
Monoclonal antibody
Target
PCSK9 [HSA:255738] [KO:K13050]
  Pathway
hsa04979  Cholesterol metabolism
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 C CARDIOVASCULAR SYSTEM
  C10 LIPID MODIFYING AGENTS
   C10A LIPID MODIFYING AGENTS, PLAIN
    C10AX Other lipid modifying agents
     C10AX13 Evolocumab
      D10557  Evolocumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Cardiovascular Agents
  Dyslipidemics, PCSK9 Inhibitor
   Evolocumab
    D10557  Evolocumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  21  Cardiovascular agents
   218  Hyperlipidemia agents
    2189  Others
     D10557  Evolocumab (USAN/INN); Evolocumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Hypolipidemic agent
  DG01946  Hypolipidemic agent
   DG03128  Anti-PCSK9 antibody and siRNA
    D10557  Evolocumab
Drug classes [BR:br08332]
 Cardiovascular agent
  DG01946  Hypolipidemic agent
   D10557  Evolocumab
Target-based classification of drugs [BR:br08310]
 Enzymes
  Hydrolases (EC3)
   Serine peptidases
    PCSK9
     D10557  Evolocumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10557
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10557
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10557
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10557
Other DBs
CAS: 1256937-27-5 1420806-15-0
PubChem: 254741519
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system